Key Takeaways
- Record quarter, but one vertical is limping: Revenue grew 18% YoY to ₹248 crores, a 14th consecutive record quarter, while Trade Generics fell to ₹30 crores after codeine-based products were discontinued.
- CDMO is the engine: Generic Formulations CDMO grew 29% YoY on customer expansion and new launches, though management warns not to treat any single quarter's vertical growth as a base rate.
- Plant 6 is the next leg: Mechanical completion is done, validations and customer audits are underway, and commercialization is on track for H1 FY27, taking capacity to ₹1,100 crores of revenue.
- Trade Generics momentum is bruised, not broken: Management calls the codeine hit temporary for a few quarters and is pushing portfolio expansion, geographic reach and sales force alignment to rebuild.
- What to watch next quarter: Plant 6 commercialization timing, whether Trade Generics shows any sequential recovery, and how the ₹3 crore quarterly depreciation step-up lands in Q3.
CDMO & Revenue Drivers
- Growth quality: Majority of growth this quarter was volume-linked, with API price impact unknown; management said the API portion should be lower and volume growth higher percent.
- Customer depth: CDMO growth came from customer expansion, deeper engagement and new product launches, with a few machines acquired for Plant 6 already used in existing Plant 2 and extension area to convert revenue this quarter.
- Gross margin mix: Higher contribution from value-added products and Exports vertical growth helped margins, offsetting the Trade Generics hit; management says this may not be a long-term thing and will be defined by product portfolio in coming quarters.
- Demand environment: No specific changes noted; no particular therapeutic area or product category driving growth, just several things continuously worked on converted into revenue this quarter in CDMO and Exports.
Windlass: "Our space is not to try to come and say that we are the cheapest and the largest. We try to go to the customers and say that we are upholding the quality. We are transparent, and we'll work with you for your needs."
Trade Generics & Institutional
- Codeine impact: India's two largest cough syrup brands are off the market; the company brought more focus to other cough syrups in its range, launched more liquid products and pack size variants, and CDMO customers who dropped codeine also required more cough syrups.
- Stagnation acknowledged: An analyst noted that even removing codeine revenue from the base, the business has been stagnant at ₹30–35 crores for 3–4 quarters; management did not dispute the stagnation but declined to give growth guidance.
- Rebuild strategy: Three focus areas: growing product offerings and SKUs, geographic expansion into other states and deepening existing presence, and ensuring execution with right hygiene and timely manner; every time people are added there is a period of nucleation before growth comes.
- Long-term confidence: Management remains extremely positive on the vertical's long-term potential, supported by favourable macroeconomic factors, increasing demand for affordable healthcare, and the internal AAA strategy.
Gupta: "The momentum has taken a hit, but that, I would say, is a temporary hit for a few quarters instead of a long-term listing. We are very confident of bringing back the momentum, bringing back good revenue numbers in this vertical."
Plant 6 & Capacity
- Commercialization timeline: On track for H1 FY27; end of Q2 or end of H1, maybe 15 days plus/minus; capacity expected to be fully coming online at end of H1.
- Nature of expansion: Plant 6 is an expansion of core business, unlike injectables which was a new dosage form; existing portfolio will be offered from Plant 6, not waiting for new product development; customers will do plant-level approvals.
- Revenue capacity: With Plant 6, company can deliver ₹1,100 crores revenue; management believes this can grow 10–15% more with efficiency initiatives; ₹1,100 crore is not a ceiling and existing facilities can be further debottlenecked.
- Depreciation step-up: Around ₹3 crore per quarter initially for first year, then declining; extra depreciation starts from Q3, with something in Q2 and Q3 it will be full.
- Utilization ceiling: 60–65% is highest peak utilization level for this kind of business, can be stretched to 70% or so; as operational capacity increases, utilization number becomes less important.
- No new capex: No immediate new capex plan beyond Plant 6; company will first focus on increasing revenue from existing plants and bringing more efficiencies in Plant 6 before starting new capex.
Windlass: "Injectables was an expansion of our periphery because we entered a new dosage form. And therefore, that required some learning side from us also and customer also testing us and also a more complex dosage form."
Capacity Philosophy & Positioning
- Incremental over scale: Management believes in incremental capacity expansion, not huge plant facilities; avoids fixed costs of underutilized capacity and desperation to fill; capacity should never become a hurdle to growth.
- The leverage argument: In any CDMO business, if a customer sees huge unutilized capacity, they understand they can get very low-margin business signed up; you go for efficiency and you lose efficiency.
- Brownfield timeline: If oral solids brownfield is compliant to new schedule, time to bring up is more like one year; a new dosage form has a different learning curve.
- Injectable capacity decision: Supportive facilities work already finished: area ready, water system extensions laid out, AHUs installed; discussions ongoing on whether to do straight capacity expansion or add more variants; when decision taken, 6–8 months to add machinery, qualify and bring online.
Gupta: "We don't think that having a huge plant facility would really do benefit us. We believe in having incremental capacity expansion... you become a little bit more desperate in terms of filling that huger plant than being able to focus... in terms of, be it operating working capital, or be it cash flows, or be it margins."
Costs, Working Capital & API Prices
- Personnel cost drivers: Annual increments, contractual manpower rising with production volume, and Uttarakhand government minimum wage increase with retrospective effect included in this quarter's personnel expense; nothing extraordinary; production and EBITDA maintained despite this.
- Minimum wage timing: Uttarakhand government notification came approximately 2–3 months before the call; management did not recall exact amount off the top of their head.
- Working capital: During the quarter, geopolitical factors caused some increase in inventory and receivable days, but by end of period and currently, overall operating working capital has been brought back to similar levels.
- Interest cost uptrend: Analyst observed interest cost increased a little and has been on an uptrend; management attributed to temporary working capital factors during the period.
- API price volatility: Prices have been varying with crude situation; early in West Asia crisis, people with lower-cost stock took advantage and increased prices; thereafter corrections and stabilization; still seeing a lot of volatility in both availability and pricing; company is cost-plus primarily.
- Partnership model on API: When company holds stock, it offers at same old price to customers due to transparency; when sharp price increases occur, customers accommodate and give benefit even on existing orders; when API prices were sharply falling, company maintained margins because customers went the extra mile to support; works like a partnership at basket level.
Windlass: "The impression that I have in my mind is of volatility only. The stability is still to be there... I would be very incorrect to say that stabilization is already appear."
Exports & Other Verticals
- Exports outlook: Exports is a higher gestation period conversion business; management remains positive on growth opportunity but cannot say what kind of growth numbers should be achieved; no guidance given.
- Exports catalysts: Focus on geography expansion, portfolio expansion, getting more plant approvals; much higher possibility of delivering good revenue in this vertical; big opportunity vertical; timing of conversion uncertain; registration work, new geographies, plant audits continuing for all plants.
- Dossier confidentiality: Dossiers previously approved in South Africa and Philippines; management declined to share which new markets added or dossier scaling details due to competitive sensitivity.
- Injectables contribution: Injectables has started participating in overall company revenue, but this is not particular to this quarter; it has been participating for some time and is not separately disclosed.
- New dosage form: No update; nothing is final.
- IPM volume growth: Management views 3.4% volume growth as a healthy sign and would like to see it continue; not claiming the tide has turned; watching growth numbers and wants to leverage them.
Windlass: "I don't want to say that the tide has turned and pretend to know more than what anybody in the industry can say. But I think this is a welcome sign, and I want to -- we are honestly watching these growth numbers and definitely want to leverage them to the best of our ability."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Plant 6 commercialization | Capacity fully coming online at end of H1 | End of Q2 / end of H1 FY27, maybe 15 days plus/minus |
| Plant 6 depreciation | Extra ₹3 crore per quarter starts | Q3 FY27, with something in Q2 and Q3 it will be full |
| Trade Generics recovery | Momentum hit is temporary; confident of bringing back momentum and good revenue numbers | A few quarters, not a long-term listing |
| Trade Generics codeine bridge | Progressively bridge the codeine gap as portfolio expands with new launches and replacements | No specific date; progressive |
| Injectable capacity expansion | When decision taken, 6–8 months to add machinery, qualify and bring online | 6–8 months from decision; decision not yet taken |
| Capacity beyond ₹1,100 crore | Can further debottleneck existing facility to increase top line from current levels | No date; after Plant 6 efficiencies |
| Next organic growth capex | Will start working on another organic growth when extra capacities needed | After increasing revenue from existing plants and Plant 6 efficiencies |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue | ₹248 crores, highest-ever quarterly revenue, +18% YoY |
| EBITDA (ex-ESOP) | ₹34 crores, +26% YoY; ESOP expenses of ₹7.2 crores excluded |
| EBITDA (reported) | ₹27 crores, including non-cash ESOP expenses of ₹7.2 crores |
| PBT (ex-ESOP) | ₹30 crores, +27% YoY |
| PAT (ex-ESOP) | ₹25 crores, +37% YoY |
| PAT (reported) | ₹18 crores, including non-cash ESOP expenses |
| EPS | ₹8.46 |
| Generic Formulations CDMO revenue | ₹207 crores, +29% YoY |
| Trade Generics & Institutional revenue | ₹30 crores, following discontinuation of codeine-based products |
| Exports revenue | ₹11 crores, +79% YoY |
| Indian pharma market volume growth | 3.4% in Q1 FY27 |
| Capacity utilization | ~65% currently; peak utilization for this business is 60–65%, stretchable to ~70% |
| Revenue capacity with Plant 6 | ₹1,100 crores, with further ₹100–150 crores possible via debottlenecking |
| Plant 6 commercialization | End of Q2 / H1 FY27, plus/minus 15 days |
| Expected quarterly depreciation increase from Plant 6 | ~₹3 crores, plus/minus 10–15%, for initial 1 year, then declining |